Contiflo-D

How is the drug helping you?  No   Yes

Contiflo-D uses

• Indications and usage
• Dosage and administration
• Dosage forms and strengths
• Contraindications
• Warnings and precautions
• Adverse reactions
• Drug interactions
• Use in specific populations
• Overdosage
• Description
• Clinical pharmacology
• Nonclinical toxicology
• Clinical studies
• How supplied/storage and handling
• Patient counseling information
• Contiflo-D reviews

1 INDICATIONS AND USAGE

Contiflo-D is a combination of Contiflo-D, a 5-alpha-reductase inhibitor, and tamsulosin, an alpha-adrenergic antagonist, indicated for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate. (1.1)

Limitations of Use: Dutasteride-containing products, including Contiflo-D, are not approved for the prevention of prostate cancer. (1.2)

1.1 Benign Prostatic Hyperplasia (BPH) Treatment

Contiflo-D^® (dutasteride and tamsulosin hydrochloride) capsules are indicated for the treatment of symptomatic BPH in men with an enlarged prostate.

1.2 Limitations of Use

Dutasteride-containing products, including Contiflo-D, are not approved for the prevention of prostate cancer.

2 DOSAGE AND ADMINISTRATION

The recommended dosage of Contiflo-D is 1 capsule (0.5 mg Contiflo-D and 0.4 mg tamsulosin hydrochloride) taken once daily approximately 30 minutes after the same meal each day.

The capsules should be swallowed whole and not chewed or opened. Contact with the contents of the Contiflo-D capsule may result in irritation of the oropharyngeal mucosa.

• Take one capsule daily approximately 30 minutes after the same meal each day. (2)
• Swallow capsule whole. (2)

3 DOSAGE FORMS AND STRENGTHS

Contiflo-D capsules, containing 0.5 mg Contiflo-D and 0.4 mg tamsulosin hydrochloride, are oblong, hard-shell capsules with a brown body and an orange cap imprinted with “GS 7CZ” in black ink.

0.5 mg Contiflo-D and 0.4 mg tamsulosin hydrochloride. (3)

4 CONTRAINDICATIONS

Contiflo-D is contraindicated for use in:

• Pregnancy. In animal reproduction and developmental toxicity studies, Contiflo-D inhibited development of male fetus external genitalia. Therefore, Contiflo-D may cause fetal harm when administered to a pregnant woman. If Contiflo-D is used during pregnancy, or if the patient becomes pregnant while taking Contiflo-D, the patient should be apprised of the potential hazard to the fetus .
• Women of childbearing potential .
• Pediatric patients .
• Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema, urticaria, pruritus, respiratory symptoms) to Contiflo-D, other 5-alpha-reductase inhibitors, tamsulosin, or any other component of Contiflo-D [see Adverse Reactions (6.2)].

• Pregnancy and women of childbearing potential. (4, 5.6, 8.1)
• Pediatric patients. (4)
• Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema, urticaria, pruritus, respiratory symptoms) to Contiflo-D, other 5-alpha-reductase inhibitors, tamsulosin, or any component of Contiflo-D. (4)

5 WARNINGS AND PRECAUTIONS

• Orthostatic hypotension and/or syncope can occur. Advise patients of symptoms related to postural hypotension and to avoid situations where injury could result if syncope occurs.
• Do not use Contiflo-D with other alpha-adrenergic antagonists, as this may increase the risk of hypotension. (5.2)
• Contiflo-D reduces serum prostate-specific antigen (PSA) concentration by approximately 50%. However, any confirmed increase in PSA while on Contiflo-D may signal the presence of prostate cancer and should be evaluated, even if those values are still within the normal range for untreated men. (5.3)
• Do not use Contiflo-D with strong inhibitors of cytochrome P450 (CYP) 3A4 (e.g., ketoconazole). Use caution in combination with moderate CYP3A4 inhibitors (e.g., erythromycin) or strong (e.g., paroxetine) or moderate CYP2D6 inhibitors, or known poor metabolizers of CYP2D6. Concomitant use with known inhibitors can cause a marked increase in drug exposure. (5.2, 7.1, 12.3)
• Exercise caution with concomitant use of phosphodiesterase-5- (PDE-5) inhibitors, as this may increase the risk of hypotension. (5.2)
• Drugs that contain Contiflo-D, including Contiflo-D, may increase the risk of high-grade prostate cancer. (5.4, 6.1)
• Prior to initiating treatment with Contiflo-D, consideration should be given to other urological conditions that may cause similar symptoms. (5.5)
• Women who are pregnant or could become pregnant should not handle Contiflo-D capsules due to potential risk to a male fetus. (5.6, 8.1)
• Advise patients about the possibility and seriousness of priapism. (5.7)
• Patients should not donate blood until 6 months after their last dose of Contiflo-D. (5.8)
• Intraoperative Floppy Iris Syndrome has been observed during cataract surgery after alpha-adrenergic antagonist exposure. Advise patients considering cataract surgery to tell their ophthalmologist that they take or have taken Contiflo-D capsules. (5.9)
• Exercise caution with concomitant use of warfarin. (5.2, 7.2. 12.3)

5.1 Orthostatic Hypotension

As with other alpha-adrenergic antagonists, orthostatic hypotension (postural hypotension, dizziness, and vertigo) may occur in patients treated with tamsulosin-containing products, including Contiflo-D, and can result in syncope. Patients starting treatment with Contiflo-D should be cautioned to avoid situations where syncope could result in an injury .

5.2 Drug-drug Interactions

Strong Inhibitors of CYP3A4

Tamsulosin-containing products, including Contiflo-D, should not be coadministered with strong CYP3A4 inhibitors as this can significantly increase tamsulosin exposure .

Inhibitors of CYP2D6 and Moderate Inhibitors of CYP3A4

Tamsulosin-containing products, including Contiflo-D, should be used with caution when coadministered with moderate inhibitors of CYP3A4 (e.g., erythromycin), strong (e.g., paroxetine) or moderate (e.g., terbinafine) inhibitors of CYP2D6, or in patients known to be poor metabolizers of CYP2D6, as there is a potential for significant increase in tamsulosin exposure .

Cimetidine

Caution is advised when tamsulosin-containing products, including Contiflo-D, are coadministered with cimetidine .

Other Alpha-adrenergic Antagonists

Tamsulosin-containing products, including Contiflo-D, should not be coadministered with other alpha-adrenergic antagonists because of the increased risk of symptomatic hypotension.

Phosphodiesterase-5 (PDE-5) Inhibitors

Caution is advised when alpha-adrenergic-antagonist-containing products, including Contiflo-D, are coadministered with PDE-5 inhibitors. Alpha-adrenergic antagonists and PDE-5 inhibitors are both vasodilators that can lower blood pressure. Concomitant use of these 2 drug classes can potentially cause symptomatic hypotension.

Warfarin

Caution should be exercised with concomitant administration of warfarin and tamsulosin-containing products, including Contiflo-D .

5.3 Effects on Prostate-specific Antigen (PSA) and the Use of PSA in Prostate Cancer Detection

Coadministration of Contiflo-D with tamsulosin resulted in similar changes to serum PSA as with Contiflo-D monotherapy.

In clinical trials, Contiflo-D reduced serum PSA concentration by approximately 50% within 3 to 6 months of treatment. This decrease was predictable over the entire range of PSA values in patients with symptomatic BPH, although it may vary in individuals. Dutasteride-containing treatment, including Contiflo-D, may also cause decreases in serum PSA in the presence of prostate cancer. To interpret serial PSAs in men treated with a dutasteride-containing product, including Contiflo-D, a new baseline PSA should be established at least 3 months after starting treatment and PSA monitored periodically thereafter. Any confirmed increase from the lowest PSA value while on a dutasteride-containing treatment, including Contiflo-D, may signal the presence of prostate cancer and should be evaluated, even if PSA levels are still within the normal range for men not taking a 5-alpha-reductase inhibitor. Noncompliance with Contiflo-D may also affect PSA test results.

To interpret an isolated PSA value in a man treated with Contiflo-D, for 3 months or more, the PSA value should be doubled for comparison with normal values in untreated men.

The free-to-total PSA ratio (percent free PSA) remains constant, even under the influence of Contiflo-D. If clinicians elect to use percent free PSA as an aid in the detection of prostate cancer in men receiving Contiflo-D, no adjustment to its value appears necessary.

5.4 Increased Risk of High-grade Prostate Cancer

In men aged 50 to 75 years with a prior negative biopsy for prostate cancer and a baseline PSA between 2.5 ng/mL and 10.0 ng/mL taking Contiflo-D in the 4-year Reduction by Contiflo-D of Prostate Cancer Events trial, there was an increased incidence of Gleason score 8 to 10 prostate cancer compared with men taking placebo (dutasteride 1.0% versus placebo 0.5%) . In a 7-year placebo-controlled clinical trial with another 5-alpha-reductase inhibitor (finasteride 5 mg, PROSCAR^®), similar results for Gleason score 8 to 10 prostate cancer were observed (finasteride 1.8% versus placebo 1.1%).

5-alpha-reductase inhibitors may increase the risk of development of high-grade prostate cancer. Whether the effect of 5-alpha-reductase inhibitors to reduce prostate volume or trial-related factors impacted the results of these trials has not been established.

5.5 Evaluation for Other Urological Diseases

Prior to initiating treatment with Contiflo-D, consideration should be given to other urological conditions that may cause similar symptoms. In addition, BPH and prostate cancer may coexist.

5.6 Exposure of Women-Risk to Male Fetus

Contiflo-D capsules should not be handled by a woman who is pregnant or who could become pregnant. Contiflo-D is absorbed through the skin and could result in unintended fetal exposure. If a woman who is pregnant or could become pregnant comes in contact with a leaking capsule, the contact area should be washed immediately with soap and water .

5.7 Priapism

Priapism (persistent painful penile erection unrelated to sexual activity) has been associated (probably less than 1 in 50,000) with the use of alpha-adrenergic antagonists, including tamsulosin, which is a component of Contiflo-D. Because this condition can lead to permanent impotence if not properly treated, patients should be advised about the seriousness of the condition.

5.8 Blood Donation

Men being treated with a dutasteride-containing product, including Contiflo-D, should not donate blood until at least 6 months have passed following their last dose. The purpose of this deferred period is to prevent administration of Contiflo-D to a pregnant female transfusion recipient.

5.9 Intraoperative Floppy Iris Syndrome

Intraoperative Floppy Iris Syndrome has been observed during cataract surgery in some patients on or previously treated with alpha-adrenergic antagonists, including tamsulosin, which is a component of Contiflo-D.

Most reports were in patients taking the alpha-adrenergic antagonist when IFIS occurred, but in some cases, the alpha-adrenergic antagonist had been stopped prior to surgery. In most of these cases, the alpha-adrenergic antagonist had been stopped recently prior to surgery (2 to 14 days), but in a few cases, IFIS was reported after the patients had been off the alpha-adrenergic antagonist for a longer period (5 weeks to 9 months). IFIS is a variant of small pupil syndrome and is characterized by the combination of a flaccid iris that billows in response to intraoperative irrigation currents, progressive intraoperative miosis despite preoperative dilation with standard mydriatic drugs, and potential prolapse of the iris toward the phacoemulsification incisions. The patient’s ophthalmologist should be prepared for possible modifications to their surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.

IFIS may increase the risk of eye complications during and after the operation. The benefit of stopping alpha-adrenergic antagonist therapy prior to cataract surgery has not been established. The initiation of therapy with tamsulosin in patients for whom cataract surgery is scheduled is not recommended.

5.10 Sulfa Allergy

In patients with sulfa allergy, allergic reaction to tamsulosin has been rarely reported. If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin-containing products, including Contiflo-D.

5.11 Effect on Semen Characteristics

Contiflo-D

The effects of Contiflo-D 0.5 mg/day on semen characteristics were evaluated in normal volunteers aged 18 to 52 (n = 27 Contiflo-D, n = 23 placebo) throughout 52 weeks of treatment and 24 weeks of post-treatment follow-up. At 52 weeks, the mean percent reductions from baseline in total sperm count, semen volume, and sperm motility were 23%, 26%, and 18%, respectively, in the Contiflo-D group when adjusted for changes from baseline in the placebo group. Sperm concentration and sperm morphology were unaffected. After 24 weeks of follow-up, the mean percent change in total sperm count in the Contiflo-D group remained 23% lower than baseline. While mean values for all semen parameters at all time-points remained within the normal ranges and did not meet predefined criteria for a clinically significant change (30%), 2 subjects in the Contiflo-D group had decreases in sperm count of greater than 90% from baseline at 52 weeks, with partial recovery at the 24-week follow-up. The clinical significance of dutasteride’s effect on semen characteristics for an individual patient’s fertility is not known.

Tamsulosin

The effects of tamsulosin hydrochloride on sperm counts or sperm function have not been evaluated.

6 ADVERSE REACTIONS

The most common adverse reactions, reported in ≥1% of subjects treated with coadministered Contiflo-D and tamsulosin are ejaculation disorders, impotence, decreased libido, dizziness, and breast disorders.

To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1 Clinical Trials Experience

There have been no clinical trials conducted with Contiflo-D; however, the clinical efficacy and safety of coadministered Contiflo-D and tamsulosin, which are individual components of Contiflo-D, have been evaluated in a multicenter, randomized, double-blind, parallel group trial (the Combination with Alpha-Blocker Therapy, or CombAT, trial). Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trial of another drug and may not reflect the rates observed in practice.

• The most common adverse reactions reported in subjects receiving coadministered Contiflo-D and tamsulosin were impotence, decreased libido, breast disorders (including breast enlargement and tenderness), ejaculation disorders, and dizziness. Ejaculation disorders occurred significantly more in subjects receiving coadministration therapy (11%) compared with those receiving Contiflo-D (2%) or tamsulosin (4%) as monotherapy.
• Trial withdrawal due to adverse reactions occurred in 6% of subjects receiving coadministered Contiflo-D and tamsulosin, and in 4% of subjects receiving Contiflo-D or tamsulosin as monotherapy. The most common adverse reaction in all treatment arms leading to trial withdrawal was erectile dysfunction (1% to 1.5%).

In the CombAT trial, over 4,800 male subjects with BPH were randomly assigned to receive 0.5 mg Contiflo-D, 0.4 mg tamsulosin hydrochloride, or coadministration therapy (0.5 mg Contiflo-D and 0.4 mg tamsulosin hydrochloride) administered once daily in a 4-year double-blind trial. Overall, 1,623 subjects received monotherapy with Contiflo-D; 1,611 subjects received monotherapy with tamsulosin; and 1,610 subjects received coadministration therapy. The population was aged 49 to 88 years (mean age: 66 years) and 88% were white. Table 1 summarizes adverse reactions reported in at least 1% of subjects receiving coadministration therapy and at a higher incidence than subjects receiving either Contiflo-D or tamsulosin as monotherapy.

^aCoadministration = AVODART^® 0.5 mg once daily plus tamsulosin 0.4 mg once daily.

^bIncludes anorgasmia, retrograde ejaculation, semen volume decreased, orgasmic sensation decreased, orgasm abnormal, ejaculation delayed, ejaculation disorder, ejaculation failure, and premature ejaculation.

^cThese sexual adverse reactions are associated with Contiflo-D treatment (including monotherapy and combination with tamsulosin). These adverse reactions may persist after treatment discontinuation. The role of Contiflo-D in this persistence is unknown.

^dIncludes erectile dysfunction and disturbance in sexual arousal.

^eIncludes libido decreased, libido disorder, loss of libido, sexual dysfunction, and male sexual dysfunction.

^fIncludes breast enlargement, gynecomastia, breast swelling, breast pain, breast tenderness, nipple pain, and nipple swelling.

Cardiac Failure

In CombAT, after 4 years of treatment, the incidence of the composite term cardiac failure in the coadministration group (12/1,610; 0.7%) was higher than in either monotherapy group: Contiflo-D, 2/1,623 (0.1%) and tamsulosin, 9/1,611 (0.6%). Composite cardiac failure was also examined in a separate 4-year placebo-controlled trial evaluating Contiflo-D in men at risk for development of prostate cancer. The incidence of cardiac failure in subjects taking Contiflo-D was 0.6% (26/4,105) compared with 0.4% (15/4,126) in subjects on placebo. A majority of subjects with cardiac failure in both trials had comorbidities associated with an increased risk of cardiac failure. Therefore, the clinical significance of the numerical imbalances in cardiac failure is unknown. No causal relationship between Contiflo-D alone or coadministered with tamsulosin and cardiac failure has been established. No imbalance was observed in the incidence of overall cardiovascular adverse events in either trial.

Additional information regarding adverse reactions in placebo-controlled trials with Contiflo-D or tamsulosin monotherapy follows.

Contiflo-D:

Long-term Treatment (Up to 4 Years): High-grade Prostate Cancer: The REDUCE trial was a randomized, double-blind, placebo-controlled trial that enrolled 8,231 men aged 50 to 75 years with a serum PSA of 2.5 ng/mL to 10 ng/mL and a negative prostate biopsy within the previous 6 months. Subjects were randomized to receive placebo (n = 4,126) or 0.5-mg daily doses of Contiflo-D (n = 4,105) for up to 4 years. The mean age was 63 years and 91% were white. Subjects underwent protocol-mandated scheduled prostate biopsies at 2 and 4 years of treatment or had “for-cause biopsies” at non-scheduled times if clinically indicated. There was a higher incidence of Gleason score 8 to 10 prostate cancer in men receiving Contiflo-D (1.0%) compared with men on placebo (0.5%) . In a 7-year placebo-controlled clinical trial with another 5-alpha-reductase inhibitor (finasteride 5 mg, PROSCAR), similar results for Gleason score 8 to 10 prostate cancer were observed (finasteride 1.8% versus placebo 1.1%).

No clinical benefit has been demonstrated in patients with prostate cancer treated with Contiflo-D.

Reproductive and Breast Disorders

In the 3 pivotal placebo-controlled BPH trials with Contiflo-D, each 4 years in duration, there was no evidence of increased sexual adverse reactions (impotence, decreased libido, and ejaculation disorder) or breast disorders with increased duration of treatment. Among these 3 trials, there was 1 case of breast cancer in the Contiflo-D group and 1 case in the placebo group. No cases of breast cancer were reported in any treatment group in the 4-year CombAT trial or the 4-year REDUCE trial.

The relationship between long-term use of Contiflo-D and male breast neoplasia is currently unknown.

Tamsulosin

According to the tamsulosin prescribing information, in two 13-week treatment trials with tamsulosin monotherapy, adverse reactions occurring in at least 2% of subjects receiving 0.4 mg tamsulosin hydrochloride and at an incidence higher than in subjects receiving placebo were: infection, asthenia, back pain, chest pain, somnolence, insomnia, rhinitis, pharyngitis, cough increased, sinusitis, and diarrhea.

Signs and Symptoms of Orthostasis: According to the tamsulosin prescribing information, in clinical trials with tamsulosin monotherapy, a positive orthostatic test result was observed in 16% (81/502) of subjects receiving 0.4 mg tamsulosin hydrochloride versus 11% (54/493) of subjects receiving placebo. Because orthostasis was detected more frequently in the tamsulosin-treated subjects than in placebo recipients, there is a potential risk of syncope .

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of the individual components of Contiflo-D. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These reactions have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to drug exposure.

Contiflo-D:

Immune System Disorders: Hypersensitivity reactions, including rash, pruritus, urticaria, localized edema, serious skin reactions, and angioedema.

Neoplasms: Male breast cancer.

Psychiatric Disorders: Depressed mood.

Reproductive System and Breast Disorders: Testicular pain and testicular swelling.

Tamsulosin:

Immune System Disorders: Hypersensitivity reactions, including rash, urticaria, pruritus, angioedema, and respiratory problems have been reported with positive rechallenge in some cases.

Cardiac Disorders: Palpitations, dyspnea, atrial fibrillation, arrhythmia, and tachycardia.

Skin Disorders: Skin desquamation, including Stevens‑Johnson syndrome, erythema multiforme, dermatitis exfoliative.

Gastrointestinal Disorders: Constipation, vomiting, dry mouth.

Reproductive System and Breast Disorders: Priapism.

Respiratory: Epistaxis.

Vascular Disorders: Hypotension.

Ophthalmologic Disorders: Blurred vision, visual impairment. During cataract surgery, a variant of small pupil syndrome known as Intraoperative Floppy Iris Syndrome (IFIS) associated with alpha-adrenergic-antagonist therapy .

7 DRUG INTERACTIONS

There have been no drug interaction trials using Contiflo-D. The following sections reflect information available for the individual components.

7.1 Cytochrome P450 3A Inhibitors

Contiflo-D

Contiflo-D is extensively metabolized in humans by the CYP3A4 and CYP3A5 isoenzymes. The effect of potent CYP3A4 inhibitors on Contiflo-D has not been studied. Because of the potential for drug-drug interactions, use caution when prescribing a dutasteride-containing product, including Contiflo-D, to patients taking potent, chronic CYP3A4 enzyme inhibitors .

Tamsulosin

Strong and Moderate Inhibitors of CYP3A4 or CYP2D6: Tamsulosin is extensively metabolized, mainly by CYP3A4 or CYP2D6.

Concomitant treatment with ketoconazole (a strong inhibitor of CYP3A4) resulted in increases in the C_max and area under the concentration-time curve (AUC) of tamsulosin by factors of 2.2 and 2.8, respectively. Concomitant treatment with paroxetine (a strong inhibitor of CYP2D6) resulted in increases in the C_max and AUC of tamsulosin by factors of 1.3 and 1.6, respectively. A similar increase in exposure is expected in poor metabolizers (PM) of CYP2D6 as compared to extensive metabolizers (EM). Since CYP2D6 PMs cannot be readily identified and the potential for significant increase in tamsulosin exposure exists when tamsulosin 0.4 mg is coadministered with strong CYP3A4 inhibitors in CYP2D6 PMs, tamsulosin 0.4 mg capsules should not be used in combination with strong inhibitors of CYP3A4 (e.g., ketoconazole). The effects of coadministration of both a CYP3A4 and a CYP2D6 inhibitor with tamsulosin have not been evaluated. However, there is a potential for significant increase in tamsulosin exposure when tamsulosin 0.4 mg is coadministered with a combination of both CYP3A4 and CYP2D6 inhibitors .

Cimetidine: Treatment with cimetidine resulted in a moderate increase in tamsulosin hydrochloride AUC (44%) .

7.2 Warfarin

Contiflo-D

Concomitant administration of Contiflo-D 0.5 mg/day for 3 weeks with warfarin does not alter the steady-state pharmacokinetics of the S- or R-warfarin isomers or alter the effect of warfarin on prothrombin time .

Tamsulosin

A definitive drug-drug interaction trial between tamsulosin hydrochloride and warfarin was not conducted. Results from limited in vitro and in vivo studies are inconclusive. Caution should be exercised with concomitant administration of warfarin and tamsulosin-containing products, including Contiflo-D .

7.3 Nifedipine, Atenolol, Enalapril

Tamsulosin

Dosage adjustments are not necessary when tamsulosin is administered concomitantly with nifedipine, atenolol, or enalapril .

7.4 Digoxin and Theophylline

Contiflo-D

Contiflo-D does not alter the steady-state pharmacokinetics of digoxin when administered concomitantly at a dose of 0.5 mg/day for 3 weeks .

Tamsulosin

Dosage adjustments are not necessary when tamsulosin is administered concomitantly with digoxin or theophylline .

7.5 Furosemide

Tamsulosin

Tamsulosin had no effect on the pharmacodynamics of furosemide. While furosemide produced an 11% to 12% reduction in tamsulosin hydrochloride C_max and AUC, these changes are expected to be clinically insignificant and do not require adjustment of the dose of tamsulosin .

7.6 Calcium Channel Antagonists

Contiflo-D

Coadministration of verapamil or diltiazem decreases Contiflo-D clearance and leads to increased exposure to Contiflo-D. The change in Contiflo-D exposure is not considered to be clinically significant. No dosage adjustment of Contiflo-D is recommended .

7.7 Cholestyramine

Contiflo-D

Administration of a single 5-mg dose of Contiflo-D followed 1 hour later by a 12-g dose of cholestyramine does not affect the relative bioavailability of Contiflo-D .

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category X. There are no adequate and well-controlled studies in pregnant women with Contiflo-D or its individual components.

Contiflo-D

Contiflo-D is contraindicated for use in women of childbearing potential and during pregnancy. Contiflo-D is a 5-alpha-reductase inhibitor that prevents conversion of testosterone to dihydrotestosterone, a hormone necessary for normal development of male genitalia. In animal reproduction and developmental toxicity studies, Contiflo-D inhibited normal development of external genitalia in male fetuses. Therefore, Contiflo-D may cause fetal harm when administered to a pregnant woman. If Contiflo-D is used during pregnancy or if the patient becomes pregnant while taking Contiflo-D, the patient should be apprised of the potential hazard to the fetus.

Abnormalities in the genitalia of male fetuses is an expected physiological consequence of inhibition of the conversion of testosterone to DHT by 5-alpha-reductase inhibitors. These results are similar to observations in male infants with genetic 5-alpha-reductase deficiency. Contiflo-D is absorbed through the skin. To avoid potential fetal exposure, women who are pregnant or could become pregnant should not handle dutasteride-containing capsules, including Contiflo-D capsules. If contact is made with leaking capsules, the contact area should be washed immediately with soap and water . Contiflo-D is secreted into semen. The highest measured semen concentration of Contiflo-D in treated men was 14 ng/mL. Assuming exposure of a 50-kg woman to 5 mL of semen and 100% absorption, the woman’s Contiflo-D concentration would be about 0.0175 ng/mL. This concentration is more than 100 times less than concentrations producing abnormalities of male genitalia in animal studies. Contiflo-D is highly protein bound in human semen (greater than 96%), which may reduce the amount of Contiflo-D available for vaginal absorption.

In an embryo-fetal development study in female rats, oral administration of Contiflo-D at doses 10 times less than the maximum recommended human dose (MRHD) of 0.5 mg daily resulted in abnormalities of male genitalia in the fetus (decreased anogenital distance at 0.05 mg/kg/day), nipple development, hypospadias, and distended preputial glands in male offspring (at all doses of 0.05, 2.5, 12.5, and 30 mg/kg/day). An increase in stillborn pups was observed at 111 times the MRHD, and reduced fetal body weight was observed at doses of about 15 times the MRHD (animal dose of 2.5 mg/kg/day). Increased incidences of skeletal variations considered to be delays in ossification associated with reduced body weight were observed at doses at about 56 times the MRHD (animal dose of 12.5 mg/kg/day).

In a rabbit embryo-fetal study, doses 28- to 93-fold the MRHD (animal doses of 30, 100, and 200 mg/kg/day) were administered orally during the period of major organogenesis (gestation days 7 to 29) to encompass the late period of external genitalia development. Histological evaluation of the genital papilla of fetuses revealed evidence of feminization of the male fetus at all doses. A second embryo-fetal study in rabbits at 0.3- to 53-fold the expected clinical exposure (animal doses of 0.05, 0.4, 3.0, and 30 mg/kg/day) also produced evidence of feminization of the genitalia in male fetuses at all doses.

In an oral pre- and post-natal development study in rats, Contiflo-D doses of 0.05, 2.5, 12.5, or 30 mg/kg/day were administered. Unequivocal evidence of feminization of the genitalia (i.e., decreased anogenital distance, increased incidence of hypospadias, nipple development) of male offspring occurred at 14- to 90-fold the MRHD (animal doses of 2.5 mg/kg/day or greater). At 0.05-fold the expected clinical exposure (animal dose of 0.05 mg/kg/day), evidence of feminization was limited to a small, but statistically significant, decrease in anogenital distance. Animal doses of 2.5 to 30 mg/kg/day resulted in prolonged gestation in the parental females and a decrease in time to vaginal patency for female offspring and a decrease in prostate and seminal vesicle weights in male offspring. Effects on newborn startle response were noted at doses greater than or equal to 12.5 mg/kg/day. Increased stillbirths were noted at 30 mg/kg/day.

In an embryo-fetal development study, pregnant rhesus monkeys were exposed intravenously to a Contiflo-D blood level comparable to the Contiflo-D concentration found in human semen. Contiflo-D was administered on gestation days 20 to 100 at doses of 400, 780, 1,325, or 2,010 ng/day (12 monkeys/group). The development of male external genitalia of monkey offspring was not adversely affected. Reduction of fetal adrenal weights, reduction in fetal prostate weights, and increases in fetal ovarian and testis weights were observed at the highest dose tested in monkeys. Based on the highest measured semen concentration of Contiflo-D in treated men (14 ng/mL), these doses represent 0.8 to 16 times the potential maximum exposure of a 50-kg human female to 5 mL semen daily from a dutasteride-treated man, assuming 100% absorption. (These calculations are based on blood levels of parent drug which are achieved at 32 to 186 times the daily doses administered to pregnant monkeys on a ng/kg basis). Contiflo-D is highly bound to proteins in human semen (greater than 96%), potentially reducing the amount of Contiflo-D available for vaginal absorption. It is not known whether rabbits or rhesus monkeys produce any of the major human metabolites.

Estimates of exposure multiples comparing animal studies to the MRHD for Contiflo-D are based on clinical serum concentration at steady state.

Tamsulosin

Administration of tamsulosin to pregnant female rats at dose levels up to approximately 50 times the human therapeutic AUC exposure (animal dose of 300 mg/kg/day) revealed no evidence of harm to the fetus. Administration of tamsulosin hydrochloride to pregnant rabbits at dose levels up to 50 mg/kg/day produced no evidence of fetal harm. However, because of the effect of Contiflo-D on the fetus, Contiflo-D is contraindicated for use in pregnant women. Estimates of exposure multiples comparing animal studies to the MRHD for tamsulosin are based on AUC.

8.3 Nursing Mothers

Contiflo-D is contraindicated for use in women of childbearing potential, including nursing women. It is not known whether Contiflo-D or tamsulosin is excreted in human milk.

8.4 Pediatric Use

Contiflo-D is contraindicated for use in pediatric patients. Safety and effectiveness of Contiflo-D in pediatric patients have not been established.

8.5 Geriatric Use

Of 1,610 male subjects treated with coadministered Contiflo-D and tamsulosin in the CombAT trial, 58% of enrolled subjects were aged 65 years and older and 13% of enrolled subjects were aged 75 years and older. No overall differences in safety or efficacy were observed between these subjects and younger subjects but greater sensitivity of some older individuals cannot be ruled out .

8.6 Renal Impairment

The effect of renal impairment on Contiflo-D and tamsulosin pharmacokinetics has not been studied using Contiflo-D. Because no dosage adjustment is necessary for Contiflo-D or tamsulosin in patients with moderate-to-severe renal impairment (10≤ CL_cr <30 mL/min/1.73 m²), no dosage adjustment is necessary for Contiflo-D in patients with moderate-to-severe renal impairment. However, patients with end-stage renal disease (CL_cr<10 mL/min/1.73 m²) have not been studied .

8.7 Hepatic Impairment

The effect of hepatic impairment on Contiflo-D and tamsulosin pharmacokinetics has not been studied using Contiflo-D. The following text reflects information available for the individual components.

Contiflo-D

The effect of hepatic impairment on Contiflo-D pharmacokinetics has not been studied. Because Contiflo-D is extensively metabolized, exposure could be higher in hepatically impaired patients. However, in a clinical trial where 60 subjects received 5 mg (10 times the therapeutic dose) daily for 24 weeks, no additional adverse events were observed compared with those observed at the therapeutic dose of 0.5 mg .

Tamsulosin

Patients with moderate hepatic impairment do not require an adjustment in tamsulosin dosage. Tamsulosin has not been studied in patients with severe hepatic impairment .

10 OVERDOSAGE

No data are available with regard to overdosage with Contiflo-D. The following text reflects information available for the individual components.

Contiflo-D

In volunteer trials, single doses of Contiflo-D up to 40 mg (80 times the therapeutic dose) for 7 days have been administered without significant safety concerns. In a clinical trial, daily doses of 5 mg (10 times the therapeutic dose) were administered to 60 subjects for 6 months with no additional adverse effects to those seen at therapeutic doses of 0.5 mg.

There is no specific antidote for Contiflo-D. Therefore, in cases of suspected overdosage symptomatic and supportive treatment should be given as appropriate, taking the long half-life of Contiflo-D into consideration.

Tamsulosin

Should overdosage of tamsulosin lead to hypotension , support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by keeping the patient in the supine position. If this measure is inadequate, then administration of intravenous fluids should be considered. If necessary, vasopressors should then be used and renal function should be monitored and supported as needed. Laboratory data indicate that tamsulosin is 94% to 99% protein bound; therefore, dialysis is unlikely to be of benefit.

11 DESCRIPTION

Contiflo-D (dutasteride and tamsulosin hydrochloride) capsules contain Contiflo-D (a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5 alpha-reductase, an intracellular enzyme that converts testosterone to DHT and tamsulosin (an antagonist of alpha_1A-adrenoceptors in the prostate). Each Contiflo-D capsule contains the following:

• One Contiflo-D oblong, opaque, dull-yellow soft gelatin capsule, containing 0.5 mg of Contiflo-D dissolved in a mixture of butylated hydroxytoluene and mono-di-glycerides of caprylic/capric acid. The inactive ingredients in the soft-gelatin capsule shell are ferric oxide (yellow), gelatin (from certified BSE-free bovine sources), glycerin, and titanium dioxide.
• Tamsulosin hydrochloride white to off-white pellets, containing 0.4 mg tamsulosin hydrochloride and the inactive ingredients: methacrylic acid copolymer dispersion, microcrystalline cellulose, talc, and triethyl citrate.

The above components are encapsulated in a hard-shell capsule made with the inactive ingredients of carrageenan, FD&C yellow 6, hypromellose, iron oxide red, potassium chloride, titanium dioxide, and imprinted with “GS 7CZ” in black ink.

Contiflo-D: Contiflo-D is a synthetic 4-azasteroid compound chemically designated as (5α,17β)-N-{2,5 bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide. The empirical formula of Contiflo-D is C₂₇H₃₀F₆N₂O₂, representing a molecular weight of 528.5 with the following structural formula:

Contiflo-D is a white to pale yellow powder with a melting point of 242° to 250°C. It is soluble in ethanol (44 mg/mL), methanol (64 mg/mL), and polyethylene glycol 400 (3 mg/mL), but it is insoluble in water.

Tamsulosin: Tamsulosin hydrochloride is a synthetic compound chemically designated as (-)-(R)-5-[2-[[2-(o-Ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide, monohydrochloride.

The empirical formula of tamsulosin hydrochloride is C₂₀H₂₈N₂O₅S-HCl. The molecular weight of tamsulosin hydrochloride is 444.97. Its structural formula is:

Tamsulosin hydrochloride is a white or almost white crystalline powder that melts with decomposition at approximately 234°C. It is sparingly soluble in water and slightly soluble in methanol, ethanol, acetone, and ethyl acetate.

Contiflo-D structural formula tamsulosin hydrochloride structural formula

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Contiflo-D is a combination of 2 drugs with different mechanisms of action to improve symptoms in patients with BPH: Contiflo-D, a 5-alpha-reductase inhibitor, and tamsulosin, an antagonist of alpha_1A-adrenoreceptors.

Contiflo-D

Contiflo-D inhibits the conversion of testosterone to DHT. DHT is the androgen primarily responsible for the initial development and subsequent enlargement of the prostate gland. Testosterone is converted to DHT by the enzyme 5 alpha-reductase, which exists as 2 isoforms, type 1 and type 2. The type 2 isoenzyme is primarily active in the reproductive tissues, while the type 1 isoenzyme is also responsible for testosterone conversion in the skin and liver.

Contiflo-D is a competitive and specific inhibitor of both type 1 and type 2 5-alpha-reductase isoenzymes, with which it forms a stable enzyme complex. Dissociation from this complex has been evaluated under in vitro and in vivo conditions and is extremely slow. Contiflo-D does not bind to the human androgen receptor.

Tamsulosin

Smooth muscle tone is mediated by the sympathetic nervous stimulation of alpha₁-adrenoceptors, which are abundant in the prostate, prostatic capsule, prostatic urethra, and bladder neck. Blockade of these adrenoceptors can cause smooth muscles in the bladder neck and prostate to relax, resulting in an improvement in urine flow rate and a reduction in symptoms of BPH.

Tamsulosin, an alpha₁-adrenoceptor blocking agent, exhibits selectivity for alpha₁-receptors in the human prostate. At least 3 discrete alpha₁-adrenoceptor subtypes have been identified: alpha_1A, alpha_1B, and alpha_1D; their distribution differs between human organs and tissue. Approximately 70% of the alpha₁-receptors in human prostate are of the alpha_1A subtype. Tamsulosin is not intended for use as an antihypertensive.

12.2 Pharmacodynamics

Contiflo-D

Effect on 5 Alpha-Dihydrotestosterone and Testosterone: The maximum effect of daily doses of Contiflo-D on the reduction of DHT is dose-dependent and is observed within 1 to 2 weeks. After 1 and 2 weeks of daily dosing with Contiflo-D 0.5 mg, median serum DHT concentrations were reduced by 85% and 90%, respectively. In patients with BPH treated with Contiflo-D 0.5 mg/day for 4 years, the median decrease in serum DHT was 94% at 1 year, 93% at 2 years, and 95% at both 3 and 4 years. The median increase in serum testosterone was 19% at both 1 and 2 years, 26% at 3 years, and 22% at 4 years, but the mean and median levels remained within the physiologic range.

In patients with BPH treated with 5 mg/day of Contiflo-D or placebo for up to 12 weeks prior to transurethral resection of the prostate, mean DHT concentrations in prostatic tissue were significantly lower in the Contiflo-D group compared with placebo. Mean prostatic tissue concentrations of testosterone were significantly higher in the Contiflo-D group compared with placebo (2,073 and 93 pg/g, respectively, P<0.001).

Adult males with genetically inherited type 2 5-alpha-reductase deficiency also have decreased DHT levels. These 5-alpha-reductase-deficient males have a small prostate gland throughout life and do not develop BPH. Except for the associated urogenital defects present at birth, no other clinical abnormalities related to 5-alpha-reductase deficiency have been observed in these individuals.

Effects on Other Hormones: In healthy volunteers, 52 weeks of treatment with Contiflo-D 0.5 mg/day (n = 26) resulted in no clinically significant change compared with placebo (n = 23) in sex hormone-binding globulin, estradiol, luteinizing hormone, follicle-stimulating hormone, thyroxine (free T4), and dehydroepiandrosterone. Statistically significant, baseline-adjusted mean increases compared with placebo were observed for total testosterone at 8 weeks (97.1 ng/dL, P<0.003) and thyroid-stimulating hormone at 52 weeks (0.4 mcIU/mL, P<0.05). The median percentage changes from baseline within the Contiflo-D group were 17.9% for testosterone at 8 weeks and 12.4% for thyroid-stimulating hormone at 52 weeks. After stopping Contiflo-D for 24 weeks, the mean levels of testosterone and thyroid-stimulating hormone had returned to baseline in the group of subjects with available data at the visit. In subjects with BPH treated with Contiflo-D in a large randomized, double-blind, placebo-controlled trial, there was a median percent increase in luteinizing hormone of 12% at 6 months and 19% at both 12 and 24 months.

Other Effects: Plasma lipid panel and bone mineral density were evaluated following 52 weeks of Contiflo-D 0.5 mg once daily in healthy volunteers. There was no change in bone mineral density as measured by dual energy x-ray absorptiometry compared with either placebo or baseline. In addition, the plasma lipid profile (i.e., total cholesterol, low density lipoproteins, high density lipoproteins, and triglycerides) was unaffected by Contiflo-D. No clinically significant changes in adrenal hormone responses to adrenocorticotropic hormone (ACTH) stimulation were observed in a subset population (n = 13) of the 1-year healthy volunteer trial.

12.3 Pharmacokinetics

The pharmacokinetics of Contiflo-D and tamsulosin from Contiflo-D are comparable to the pharmacokinetics of Contiflo-D and tamsulosin when administered separately.

Absorption

The pharmacokinetic parameters of Contiflo-D and tamsulosin observed after administration of Contiflo-D in a single-dose, randomized, 3-period, partial cross-over trial are summarized in Table 2 below.

^a Median (range).

^b N = 91.

Contiflo-D: Following administration of a single 0.5-mg dose of a soft gelatin capsule, time to peak absolute bioavailability in 5 healthy subjects is approximately 60% (range: 40% to 94%).

Tamsulosin: Absorption of tamsulosin is essentially complete (>90%) following oral administration of 0.4-mg tamsulosin hydrochloride capsules under fasting conditions. Tamsulosin exhibits linear kinetics following single and multiple dosing, with achievement of steady-state concentrations by the fifth day of once-daily dosing.

Effect of Food

Food does not affect the pharmacokinetics of Contiflo-D following administration of Contiflo-D. However, a mean 30% decrease in tamsulosin C_max was observed when Contiflo-D was administered with food, similar to that seen when tamsulosin monotherapy was administered under fed versus fasting conditions.

Distribution

Contiflo-D: Pharmacokinetic data following single and repeat oral doses show that Contiflo-D has a large volume of distribution (300 to 500 L). Contiflo-D is highly bound to plasma albumin (99.0%) and alpha-1 acid glycoprotein (AAG, 96.6%).

In a trial of healthy subjects (n = 26) receiving Contiflo-D 0.5 mg/day for 12 months, semen Contiflo-D concentrations averaged 3.4 ng/mL (range: 0.4 to 14 ng/mL) at 12 months and, similar to serum, achieved steady-state concentrations at 6 months. On average, at 12 months 11.5% of serum Contiflo-D concentrations partitioned into semen.

Tamsulosin: The mean steady-state apparent volume of distribution of tamsulosin after intravenous administration to 10 healthy male adults was 16 L, which is suggestive of distribution into extracellular fluids in the body.

Tamsulosin is extensively bound to human plasma proteins (94% to 99%), primarily AAG, with linear binding over a wide concentration range (20 to 600 ng/mL). The results of 2-way in vitro studies indicate that the binding of tamsulosin to human plasma proteins is not affected by amitriptyline, diclofenac, glyburide, simvastatin plus simvastatin-hydroxy acid metabolite, warfarin, diazepam, or propranolol. Likewise, tamsulosin had no effect on the extent of binding of these drugs.

Metabolism

Contiflo-D: Contiflo-D is extensively metabolized in humans. In vitro studies showed that Contiflo-D is metabolized by the CYP3A4 and CYP3A5 isoenzymes. Both of these isoenzymes produced the 4′-hydroxydutasteride, 6-hydroxydutasteride, and the 6,4′-dihydroxydutasteride metabolites. In addition, the 15-hydroxydutasteride metabolite was formed by CYP3A4. Contiflo-D is not metabolized in vitro by human cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1. In human serum following dosing to steady state, unchanged Contiflo-D, 3 major metabolites (4′-hydroxydutasteride, 1,2-dihydrodutasteride, and 6-hydroxydutasteride), and 2 minor metabolites (6,4′-dihydroxydutasteride and 15-hydroxydutasteride), as assessed by mass spectrometric response, have been detected. The absolute stereochemistry of the hydroxyl additions in the 6 and 15 positions is not known. In vitro, the 4′-hydroxydutasteride and 1,2-dihydrodutasteride metabolites are much less potent than Contiflo-D against both isoforms of human 5α-reductase. The activity of 6β-hydroxydutasteride is comparable to that of Contiflo-D.

Tamsulosin: There is no enantiomeric bioconversion from tamsulosin [R(-) isomer] to the S(+) isomer in humans. Tamsulosin is extensively metabolized by cytochrome P450 enzymes in the liver and less than 10% of the dose is excreted in urine unchanged. However, the pharmacokinetic profile of the metabolites in humans has not been established. In vitro studies indicate that CYP3A4 and CYP2D6 are involved in metabolism of tamsulosin as well as some minor participation of other CYP isoenzymes. Inhibition of hepatic drug-metabolizing enzymes may lead to increased exposure to tamsulosin . The metabolites of tamsulosin undergo extensive conjugation to glucuronide or sulfate prior to renal excretion.

Incubations with human liver microsomes showed no evidence of clinically significant metabolic interactions between tamsulosin and amitriptyline, albuterol, glyburide, and finasteride. However, results of the in vitro testing of the tamsulosin interaction with diclofenac and warfarin were equivocal.

Excretion

Contiflo-D: Contiflo-D and its metabolites were excreted mainly in feces. As a percent of dose, there was approximately 5% unchanged Contiflo-D (approximately 1% to approximately 15%) and 40% as dutasteride-related metabolites (approximately 2% to approximately 90%). Only trace amounts of unchanged Contiflo-D were found in urine (<1%). Therefore, on average, the dose unaccounted for approximated 55% (range: 5% to 97%). The terminal elimination half-life of Contiflo-D is approximately 5 weeks at steady state. The average steady-state serum Contiflo-D concentration was 40 ng/mL following 0.5 mg/day for 1 year. Following daily dosing, Contiflo-D serum concentrations achieve 65% of steady-state concentration after 1 month and approximately 90% after 3 months. Due to the long half-life of Contiflo-D, serum concentrations remain detectable (greater than 0.1 ng/mL) for up to 4 to 6 months after discontinuation of treatment.

Tamsulosin: On administration of the radiolabeled dose of tamsulosin to 4 healthy volunteers, 97% of the administered radioactivity was recovered, with urine (76%) representing the primary route of excretion compared with feces (21%) over 168 hours.

Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin in plasma ranges from 5 to 7 hours. Because of absorption rate-controlled pharmacokinetics with tamsulosin hydrochloride capsules, the apparent half-life of tamsulosin is approximately 9 to 13 hours in healthy volunteers and 14 to 15 hours in the target population.

Tamsulosin undergoes restrictive clearance in humans, with a relatively low systemic clearance (2.88 L/h).

Specific Populations

Pediatric: The pharmacokinetics of Contiflo-D and tamsulosin administered together have not been investigated in subjects younger than 18 years.

Geriatric: Contiflo-D and tamsulosin pharmacokinetics using Contiflo-D have not been studied in geriatric patients. The following text reflects information for the individual components.

Contiflo-D: No dosage adjustment is necessary in the elderly. The pharmacokinetics and pharmacodynamics of Contiflo-D were evaluated in 36 healthy male subjects aged between 24 and 87 years following administration of a single 5-mg dose of Contiflo-D. In this single-dose trial, Contiflo-D half-life increased with age (approximately 170 hours in men aged 20 to 49 years, approximately 260 hours in men aged 50 to 69 years, and approximately 300 hours in men older than 70 years).

Tamsulosin: Cross-study comparison of tamsulosin overall exposure (AUC) and half-life indicate that the pharmacokinetic disposition of tamsulosin may be slightly prolonged in geriatric males compared with young, healthy male volunteers. Intrinsic clearance is independent of tamsulosin binding to AAG, but diminishes with age, resulting in a 40% overall higher exposure (AUC) in subjects aged 55 to 75 years compared with subjects aged 20 to 32 years.

Gender: Contiflo-D: Contiflo-D is contraindicated in pregnancy and women of childbearing potential and is not indicated for use in other women . The pharmacokinetics of Contiflo-D in women have not been studied.

Tamsulosin: Tamsulosin is not indicated for use in women. No information is available on the pharmacokinetics of tamsulosin in women.

Race: The effect of race on pharmacokinetics of Contiflo-D and tamsulosin administered together or separately has not been studied.

Renal Impairment: The effect of renal impairment on Contiflo-D and tamsulosin pharmacokinetics has not been studied using Contiflo-D. The following text reflects information for the individual components.

Contiflo-D: The effect of renal impairment on Contiflo-D pharmacokinetics has not been studied. However, less than 0.1% of a steady-state 0.5-mg dose of Contiflo-D is recovered in human urine, so no adjustment in dosage is anticipated for patients with renal impairment.

Tamsulosin: The pharmacokinetics of tamsulosin have been compared in 6 subjects with mild-moderate (30≤ CL_cr <70 mL/min/1.73 m²) or moderate-severe (10≤ CL_cr <30 mL/min/1.73 m²) renal impairment and 6 normal subjects (CL_cr >90 mL/min/1.73 m²). While a change in the overall plasma concentration of tamsulosin was observed as the result of altered binding to AAG, the unbound (active) concentration of tamsulosin, as well as the intrinsic clearance, remained relatively constant. Therefore, patients with renal impairment do not require an adjustment in tamsulosin dosing. However, patients with end-stage renal disease (CL_cr <10 mL/min/1.73 m²) have not been studied.

Hepatic Impairment: The effect of hepatic impairment on Contiflo-D and tamsulosin pharmacokinetics has not been studied using Contiflo-D. The following text reflects information available for the individual components.

Contiflo-D: The effect of hepatic impairment on Contiflo-D pharmacokinetics has not been studied. Because Contiflo-D is extensively metabolized, exposure could be higher in hepatically impaired patients.

Tamsulosin: The pharmacokinetics of tamsulosin have been compared in 8 subjects with moderate hepatic impairment (Child-Pugh classification: Grades A and B) and 8 normal subjects. While a change in the overall plasma concentration of tamsulosin was observed as the result of altered binding to AAG, the unbound (active) concentration of tamsulosin does not change significantly with only a modest (32%) change in intrinsic clearance of unbound tamsulosin. Therefore, patients with moderate hepatic impairment do not require an adjustment in tamsulosin dosage. Tamsulosin has not been studied in patients with severe hepatic impairment.

Drug Interactions

There have been no drug interaction studies using Contiflo-D. The following text reflects information available for the individual components.

Cytochrome P450 Inhibitors: Contiflo-D: No clinical drug interaction trials have been performed to evaluate the impact of CYP3A enzyme inhibitors on Contiflo-D pharmacokinetics. However, based on in vitro data, blood concentrations of Contiflo-D may increase in the presence of inhibitors of CYP3A4/5 such as ritonavir, ketoconazole, verapamil, diltiazem, cimetidine, troleandomycin, and ciprofloxacin.

Contiflo-D does not inhibit the in vitro metabolism of model substrates for the major human cytochrome P450 isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) at a concentration of 1,000 ng/mL, 25 times greater than steady-state serum concentrations in humans.

Tamsulosin: Strong and Moderate Inhibitors of CYP3A4 or CYP2D6: The effects of ketoconazole (a strong inhibitor of CYP3A4) at 400 mg once daily for 5 days on the pharmacokinetics of a single tamsulosin hydrochloride capsule 0.4-mg dose was investigated in 24 healthy volunteers (age range: 23 to 47 years). Concomitant treatment with ketoconazole resulted in increases in the C_max and AUC of tamsulosin by factors of 2.2 and 2.8, respectively. The effects of concomitant administration of a moderate CYP3A4 inhibitor (e.g., erythromycin) on the pharmacokinetics of tamsulosin have not been evaluated.

The effects of paroxetine (a strong inhibitor of CYP2D6) at 20 mg once daily for 9 days on the pharmacokinetics of a single tamsulosin capsule 0.4-mg dose was investigated in 24 healthy volunteers (age range: 23 to 47 years). Concomitant treatment with paroxetine resulted in increases in the C_max and AUC of tamsulosin by factors of 1.3 and 1.6, respectively. A similar increase in exposure is expected in poor metabolizers (PM) of CYP2D6 as compared with extensive metabolizers (EM). A fraction of the population (about 7% of whites and 2% of African-Americans) are CYP2D6 PMs. Since CYP2D6 PMs cannot be readily identified and the potential for significant increase in tamsulosin exposure exists when tamsulosin 0.4 mg is coadministered with strong CYP3A4 inhibitors in CYP2D6 PMs, tamsulosin 0.4-mg capsules should not be used in combination with strong inhibitors of CYP3A4 (e.g., ketoconazole).

The effects of concomitant administration of a moderate CYP2D6 inhibitor (e.g., terbinafine) on the pharmacokinetics of tamsulosin have not been evaluated.

The effects of coadministration of both a CYP3A4 and a CYP2D6 inhibitor with tamsulosin capsules have not been evaluated. However, there is a potential for significant increase in tamsulosin exposure when tamsulosin 0.4 mg is coadministered with a combination of both CYP3A4 and CYP2D6 inhibitors.

Cimetidine: The effects of cimetidine at the highest recommended dose (400 mg every 6 hours for 6 days) on the pharmacokinetics of a single tamsulosin capsule 0.4-mg dose was investigated in 10 healthy volunteers (age range: 21 to 38 years). Treatment with cimetidine resulted in a significant decrease (26%) in the clearance of tamsulosin hydrochloride, which resulted in a moderate increase in tamsulosin hydrochloride AUC (44%).

Alpha-adrenergic Antagonists: Contiflo-D: In a single-sequence, crossover trial in healthy volunteers, the administration of tamsulosin or terazosin in combination with Contiflo-D had no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. Although the effect of administration of tamsulosin or terazosin on Contiflo-D pharmacokinetic parameters was not evaluated, the percent change in DHT concentrations was similar for Contiflo-D, alone or in combination with tamsulosin or terazosin.

Warfarin: Contiflo-D: In a trial of 23 healthy volunteers, 3 weeks of treatment with Contiflo-D 0.5 mg/day did not alter the steady-state pharmacokinetics of the S- or R-warfarin isomers or alter the effect of warfarin on prothrombin time when administered with warfarin.

Tamsulosin: A definitive drug-drug interaction trial between tamsulosin and warfarin was not conducted. Results from limited in vitro and in vivo studies are inconclusive. Therefore, caution should be exercised with concomitant administration of warfarin and tamsulosin.

Nifedipine, Atenolol, Enalapril: Tamsulosin: In 3 trials in hypertensive subjects (age range: 47 to 79 years) whose blood pressure was controlled with stable doses of nifedipine extended-release, atenolol, or enalapril for at least 3 months, tamsulosin hydrochloride capsules 0.4 mg for 7 days followed by tamsulosin hydrochloride capsules 0.8 mg for another 7 days (n = 8 per trial) resulted in no clinically significant effects on blood pressure and pulse rate compared with placebo (n = 4 per trial). Therefore, dosage adjustments are not necessary when tamsulosin is administered concomitantly with nifedipine extended-release, atenolol, or enalapril.

Digoxin and Theophylline: Contiflo-D: In a trial of 20 healthy volunteers, Contiflo-D did not alter the steady-state pharmacokinetics of digoxin when administered concomitantly at a dose of 0.5 mg/day for 3 weeks.

Tamsulosin: In 2 trials in healthy volunteers (n = 10 per trial; age range: 19 to 39 years) receiving tamsulosin capsules 0.4 mg/day for 2 days, followed by tamsulosin capsules 0.8 mg/day for 5 to 8 days, single intravenous doses of digoxin 0.5 mg or theophylline 5 mg/kg resulted in no change in the pharmacokinetics of digoxin or theophylline. Therefore, dosage adjustments are not necessary when a tamsulosin capsule is administered concomitantly with digoxin or theophylline.

Furosemide: Tamsulosin: The pharmacokinetic and pharmacodynamic interaction between tamsulosin hydrochloride capsules 0.8 mg/day (steady-state) and furosemide 20 mg intravenously (single dose) was evaluated in 10 healthy volunteers (age range: 21 to 40 years). Tamsulosin had no effect on the pharmacodynamics (excretion of electrolytes) of furosemide. While furosemide produced an 11% to 12% reduction in tamsulosin C_max and AUC, these changes are expected to be clinically insignificant and do not require dose adjustment for tamsulosin.

Calcium Channel Antagonists: Contiflo-D: In a population pharmacokinetics analysis, a decrease in clearance of Contiflo-D was noted when coadministered with the CYP3A4 inhibitors verapamil (-37%, n = 6) and diltiazem (-44%, n = 5). In contrast, no decrease in clearance was seen when amlodipine, another calcium channel antagonist that is not a CYP3A4 inhibitor, was coadministered with Contiflo-D (+7%, n = 4). The decrease in clearance and subsequent increase in exposure to Contiflo-D in the presence of verapamil and diltiazem is not considered to be clinically significant. No dosage adjustment is recommended.

Cholestyramine: Contiflo-D: Administration of a single 5-mg dose of Contiflo-D followed 1 hour later by 12 g cholestyramine did not affect the relative bioavailability of Contiflo-D in 12 normal volunteers.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

No non-clinical studies have been conducted with Contiflo-D. The following information is based on studies performed with Contiflo-D or tamsulosin.

Carcinogenesis

Contiflo-D: A 2-year carcinogenicity study was conducted in B6C3F1 mice at doses of 3, 35, 250, and 500 mg/kg/day for males and 3, 35, and 250 mg/kg/day for females; an increased incidence of benign hepatocellular adenomas was noted at 250 mg/kg/day in female mice only. Two of the 3 major human metabolites have been detected in mice. The exposure to these metabolites in mice is either lower than in humans or is not known.

In a 2-year carcinogenicity study in Han Wistar rats, at doses of 1.5, 7.5, and 53 mg/kg/day in males and 0.8, 6.3, and 15 mg/kg/day in females, there was an increase in Leydig cell adenomas in the testes at 135-fold the MRHD (53 mg/kg/day and greater). An increased incidence of Leydig cell hyperplasia was present at 52-fold the MRHD (male rat doses of 7.5 mg/kg/day and greater). A positive correlation between proliferative changes in the Leydig cells and an increase in circulating luteinizing hormone levels has been demonstrated with 5-alpha-reductase inhibitors and is consistent with an effect on the hypothalamic-pituitary-testicular axis following 5-alpha-reductase inhibition. At tumorigenic doses, luteinizing hormone levels in rats were increased by 167%. In this study, the major human metabolites were tested for carcinogenicity at approximately 1 to 3 times the expected clinical exposure.

Tamsulosin: In a rat carcinogenicity assay, no increases in tumor incidence was observed in rats administered up to 3 times the MRHD of 0.8 mg/day (based on AUC of animal doses up to 43 mg/kg/day in males and up to 52 mg/kg/day in females), with the exception of a modest increase in the frequency of mammary gland fibroadenomas in female rats receiving doses of 5.4 mg/kg or greater.

In a carcinogenicity assay, mice were administered up to 8 times the MRHD of tamsulosin (oral doses up to 127 mg/kg/day in males and 158 mg/kg/day in females). There were no significant tumor findings in male mice. Female mice treated for 2 years with the 2 highest doses of 45 and 158 mg/kg/day had statistically significant increases in the incidence of mammary gland fibroadenomas (P<0.0001) and adenocarcinomas.

The increased incidences of mammary gland neoplasms in female rats and mice were considered secondary to tamsulosin-induced hyperprolactinemia. It is not known if tamsulosin elevates prolactin in humans. The relevance for human risk of the findings of prolactin-mediated endocrine tumors in rodents is not known.

Mutagenesis

Contiflo-D: Contiflo-D was tested for genotoxicity in a bacterial mutagenesis assay (Ames test), a chromosomal aberration assay in Chinese hamster ovary (CHO) cells, and a micronucleus assay in rats. The results did not indicate any genotoxic potential of the parent drug. Two major human metabolites were also negative in either the Ames test or an abbreviated Ames test.

Tamsulosin: Tamsulosin produced no evidence of mutagenic potential in vitro in the Ames reverse mutation test, mouse lymphoma thymidine kinase assay, unscheduled DNA repair synthesis assay, and chromosomal aberration assays in CHO cells or human lymphocytes. There were no mutagenic effects in the in vivo sister chromatid exchange and mouse micronucleus assay.

Impairment of Fertility

Contiflo-D: Treatment of sexually mature male rats with Contiflo-D at 0.1- to 110-fold the MRHD (animal doses of 0.05, 10, 50, and 500 mg/kg/day for up to 31 weeks) resulted in dose- and time-dependent decreases in fertility; reduced cauda epididymal (absolute) sperm counts but not sperm concentration (at 50 and 500 mg/kg/day); reduced weights of the epididymis, prostate, and seminal vesicles; and microscopic changes in the male reproductive organs. The fertility effects were reversed by recovery week 6 at all doses, and sperm counts were normal at the end of a 14-week recovery period. The 5-alpha-reductase–related changes consisted of cytoplasmic vacuolation of tubular epithelium in the epididymides and decreased cytoplasmic content of epithelium, consistent with decreased secretory activity in the prostate and seminal vesicles. The microscopic changes were no longer present at recovery week 14 in the low-dose group and were partly recovered in the remaining treatment groups. Low levels of Contiflo-D (0.6 to 17 ng/mL) were detected in the serum of untreated female rats mated to males dosed at 10, 50, or 500 mg/kg/day for 29 to 30 weeks.

In a fertility study in female rats, oral administration of Contiflo-D at doses of 0.05, 2.5, 12.5, and 30 mg/kg/day resulted in reduced litter size, increased embryo resorption and feminization of male fetuses (decreased anogenital distance) at 2- to 10-fold the MRHD (animal doses of 2.5 mg/kg/day or greater). Fetal body weights were also reduced at less than 0.02-fold the MRHD in rats (0.5 mg/kg/day).

Tamsulosin: Studies in rats revealed significantly reduced fertility in males at approximately 50 times the MRHD based on AUC (single or multiple daily doses of 300 mg/kg/day of tamsulosin hydrochloride). The mechanism of decreased fertility in male rats is considered to be an effect of the compound on the vaginal plug formation possibly due to changes of semen content or impairment of ejaculation. The effects on fertility were reversible showing improvement by 3 days after a single dose and 4 weeks after multiple dosing. Effects on fertility in males were completely reversed within nine weeks of discontinuation of multiple dosing. Multiple doses of 0.2 and 16 times the MRHD (animal doses of 10 and 100 mg/kg/day tamsulosin hydrochloride) did not significantly alter fertility in male rats. Effects of tamsulosin on sperm counts or sperm function have not been evaluated.

Studies in female rats revealed significant reductions in fertility after single or multiple dosing with 300 mg/kg/day of the R-isomer or racemic mixture of tamsulosin hydrochloride, respectively. In female rats, the reductions in fertility after single doses were considered to be associated with impairments in fertilization. Multiple dosing with 10 or 100 mg/kg/day of the racemic mixture did not significantly alter fertility in female rats.

Estimates of exposure multiples comparing animal studies with the MRHD for Contiflo-D are based on clinical serum concentration at steady state.

Estimates of exposure multiples comparing animal studies with the MRHD for tamsulosin are based on AUC.

13.2 Animal Toxicology and/or Pharmacology

Central Nervous System Toxicology Studies

Contiflo-D: In rats and dogs, repeated oral administration of Contiflo-D resulted in some animals showing signs of non-specific, reversible, centrally-mediated toxicity without associated histopathological changes at exposures 425- and 315-fold the expected clinical exposure (of parent drug), respectively.

14 CLINICAL STUDIES

The trial supporting the efficacy of Contiflo-D was a 4-year multicenter, randomized, double-blind, parallel-group trial (CombAT trial) investigating the efficacy of the coadministration of Contiflo-D 0.5 mg/day and tamsulosin hydrochloride 0.4 mg/day (n = 1,610) compared with Contiflo-D alone (n = 1,623) or tamsulosin alone (n = 1,611). Subjects were at least 50 years of age with a serum PSA ≥1.5 ng/mL and <10 ng/mL and BPH diagnosed by medical history and physical examination, including enlarged prostate (≥30 cc) and BPH symptoms that were moderate to severe according to the International Prostate Symptom Score (IPSS). Eighty-eight percent (88%) of the enrolled trial population was white. Approximately 52% of subjects had previous exposure to 5-alpha-reductase inhibitor or alpha-adrenergic antagonist treatment. Of the 4,844 subjects randomly assigned to receive treatment, 69% of subjects in the coadministration group, 67% in the Contiflo-D group, and 61% in the tamsulosin group completed 4 years of double-blind treatment.

Effect on Symptom Score

Symptoms were quantified using the first 7 questions of the International Prostate Symptom Score (IPSS). The baseline score was approximately 16.4 units for each treatment group. Coadministration therapy was statistically superior to each of the monotherapy treatments in decreasing symptom score at Month 24, the primary time point for this endpoint. At Month 24, the mean changes from baseline (±SD) in IPSS total symptom scores were -6.2 (±7.14) for the coadministration group, -4.9 (±6.81) for Contiflo-D, and -4.3 (±7.01) for tamsulosin, with a mean difference between coadministration and Contiflo-D of -1.3 units (P<0.001; [95% CI: -1.69, -0.86]), and between coadministration and tamsulosin of -1.8 units (P<0.001; [95% CI: -2.23, -1.40]). A significant difference was seen by Month 9 and continued through Month 48. At Month 48 the mean changes from baseline (±SD) in IPSS total symptom scores were -6.3 (±7.40) for coadministration, -5.3 (±7.14) for Contiflo-D, and -3.8 (±7.74) for tamsulosin, with a mean difference between coadministration and Contiflo-D of -0.96 units (P<0.001; [95% CI: -1.40, -0.52]), and between coadministration and tamsulosin of -2.5 units (P<0.001; [95% CI: -2.96, -2.07]). See Figure 1.

Figure 1. International Prostate Symptom Score Change from Baseline over a 48-Month Period (Randomized, Double-blind, Parallel-group Trial [CombAT Trial])

Effect on Acute Urinary Retention (AUR) or the Need for BPH-related Surgery

After 4 years of treatment, coadministration therapy with Contiflo-D and tamsulosin did not provide benefit over Contiflo-D monotherapy in reducing the incidence of AUR or BPH-related surgery.

In separate 2-year randomized, double-blind trials, compared with placebo, Contiflo-D monotherapy was associated with a statistically significantly lower incidence of AUR (1.8% for Contiflo-D versus 4.2% for placebo; 57% reduction in risk) and with a statistically significantly lower incidence of BPH-related surgery (2.2% for Contiflo-D versus. 4.1% for placebo; 48% reduction in risk).

Effect on Maximum Urine Flow Rate

The baseline Q_max was approximately 10.7 mL/sec for each treatment group. Coadministration therapy was statistically superior to each of the monotherapy treatments in increasing Q_max at Month 24, the primary time point for this endpoint. At Month 24, the mean increases from baseline (±SD) in Q_max were 2.4 (±5.26) mL/sec for coadministration group, 1.9 (±5.10) mL/sec for Contiflo-D, and 0.9 (±4.57) mL/sec for tamsulosin, with a mean difference between coadministration and Contiflo-D of 0.5 mL/sec (P = 0.003; [95% CI: 0.17, 0.84]), and between coadministration and tamsulosin of 1.5 mL/sec (P<0.001; [95% CI: 1.19, 1.86]). This difference was seen by Month 6 and continued through Month 24. See Figure 2.

The additional improvement in Q_max of coadministration therapy over Contiflo-D monotherapy was no longer statistically significant at Month 48.

Figure 2. Q_max Change from Baseline over a 24-Month Period (Randomized, Double-blind, Parallel-group Trial [CombAT Trial])

Effect on Prostate Volume

The mean prostate volume at trial entry was approximately 55 cc. At Month 24, the primary time point for this endpoint, the mean percent changes from baseline (±SD) in prostate volume were -26.9% (±22.57) for coadministration therapy, -28.0% (±24.88) for Contiflo-D, and 0% (±31.14) for tamsulosin, with a mean difference between coadministration and Contiflo-D of 1.1% (P = NS; [95% CI: -0.6, 2.8]), and between coadministration and tamsulosin of -26.9% (P<0.001; [95% CI: -28.9, -24.9]). Similar changes were seen at Month 48: -27.3% (±24.91) for coadministration therapy, -28.0% (±25.74) for Contiflo-D, and +4.6% (±35.45) for tamsulosin.

Figure 1 Figure 2. Qmax Change from Baseline (CombAT study)

16 HOW SUPPLIED/STORAGE AND HANDLING

Contiflo-D capsules, containing 0.5 mg Contiflo-D and 0.4 mg tamsulosin hydrochloride, are oblong hard-shell capsules with a brown body and an orange cap imprinted with “GS 7CZ” in black ink. They are available in bottles with child-resistant closures as follows:

Bottle of 30 (NDC 0173-0809-13).

Bottle of 90 (NDC 0173-0809-59).

Store at 25°C (77°F); excursions permitted 15° to 30°C (59° to 86°F). Capsules may become deformed and/or discolored if kept at high temperatures.

Contiflo-D is absorbed through the skin. Contiflo-D capsules should not be handled by women who are pregnant or who could become pregnant because of the potential for absorption of Contiflo-D and the subsequent potential risk to a developing male fetus .

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Orthostatic Hypotension

Inform patients about the possible occurrence of symptoms related to orthostatic hypotension, such as dizziness and vertigo, and the potential risk of syncope when taking Contiflo-D. Caution patients starting treatment with Contiflo-D to avoid situations where injury could result should syncope occur (e.g., driving, operating machinery, performing hazardous tasks). Advise patients to sit or lie down at the first signs of orthostatic hypotension .

PSA Monitoring

Inform patients that Contiflo-D reduces serum PSA levels by approximately 50% within 3 to 6 months of therapy, although it may vary for each individual. For patients undergoing PSA screening, increases in PSA levels while on treatment with Contiflo-D may signal the presence of prostate cancer and should be evaluated by a healthcare provider .

Risk of High-grade Prostate Cancer

Inform patients that there was an increase in high-grade prostate cancer in men treated with 5-alpha-reductase inhibitors (which are indicated for BPH treatment), including Contiflo-D, which is a component of Contiflo-D, compared with those treated with placebo in trials looking at the use of these drugs to reduce the risk of prostate cancer .

Exposure of Women-Risk to Male Fetus

Inform patients that Contiflo-D capsules should not be handled by a woman who is pregnant or who could become pregnant because of the potential for absorption of Contiflo-D and the subsequent potential risk to a developing male fetus. Contiflo-D is absorbed through the skin and could result in unintended fetal exposure. If a pregnant woman or woman of childbearing potential comes in contact with leaking Contiflo-D capsules, the contact area should be washed immediately with soap and water .

Instructions for Use

Contiflo-D capsules should be swallowed whole and not chewed, crushed, or opened. Contiflo-D capsules may become deformed and/or discolored if kept at high temperatures. If this occurs, capsules should not be used.

Priapism

Inform patients about the possibility of priapism as a result of treatment with Contiflo-D or other alpha-adrenergic-antagonist-containing medications. Inform patients that this reaction is extremely rare, but can lead to permanent erectile dysfunction if not brought to immediate medical attention .

Blood Donation

Inform men treated with Contiflo-D that they should not donate blood until at least 6 months following their last dose to prevent pregnant women from receiving Contiflo-D through blood transfusion . Serum levels of Contiflo-D are detectable for 4 to 6 months after treatment ends .

Intraoperative Floppy Iris Syndrome (IFIS)

Advise patients considering cataract surgery to tell their ophthalmologist that they take or have taken Contiflo-D, an alpha adrenergic antagonist-containing product .

Contiflo-D and AVODART are trademarks of the GSK group of companies.

The other brands listed are trademarks of their respective owners and are not trademarks of the GSK group of companies. The makers of these brands are not affiliated with and do not endorse the GSK group of companies or its products.

Manufactured for:

GlaxoSmithKline

Research Triangle Park, NC 27709

©2015, the GSK group of companies. All rights reserved.

JLN:10PI

PATIENT INFORMATION

Contiflo-D^® [JAY-lin]

(dutasteride and tamsulosin hydrochloride)

capsules

Contiflo-D is for use by men only.

Read this patient information before you start taking Contiflo-D and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.

What is Contiflo-D?

Contiflo-D is a prescription medicine that contains 2 medicines: Contiflo-D and tamsulosin. Contiflo-D is used to treat the symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate.

Who should not take Contiflo-D?

Do Not Take Contiflo-D if you are:

• pregnant or could become pregnant. Contiflo-D may harm your unborn baby. Pregnant women should not touch Contiflo-D capsules. If a woman who is pregnant with a male baby gets enough Contiflo-D in her body by swallowing or touching Contiflo-D, the male baby may be born with sex organs that are not normal. If a pregnant woman or woman of childbearing potential comes in contact with leaking Contiflo-D capsules, the contact area should be washed immediately with soap and water.
• a child or teenager.
• allergic to Contiflo-D, tamsulosin, or any of the ingredients in Contiflo-D. See the end of this leaflet for a complete list of ingredients in Contiflo-D.
• taking another medicine that contains an alpha-blocker.
• allergic to other 5-alpha-reductase inhibitors, for example, PROSCAR^® (finasteride) Tablets.

What should I tell my healthcare provider before taking Contiflo-D?

Before you take Contiflo-D, tell your healthcare provider if you:

• have a history of low blood pressure
• take medicines to treat high blood pressure
• plan to have cataract surgery
• have liver problems
• are allergic to sulfa medications
• have any other medical conditions

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Contiflo-D and other medicines may affect each other, causing side effects. Contiflo-D may affect the way other medicines work, and other medicines may affect how Contiflo-D works.

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

How should I take Contiflo-D?

• Take Contiflo-D exactly as your healthcare provider tells you to take it.
• Swallow Contiflo-D capsules whole. Do not crush, chew, or open Contiflo-D capsules because the contents of the capsule may irritate your lips, mouth, or throat.
• Take your Contiflo-D 1 time each day, about 30 minutes after the same meal every day. For example, you may take Contiflo-D 30 minutes after dinner every day.
• If you miss a dose, you can take it later that same day, 30 minutes after a meal. Do not take 2 JALYN capsules in the same day. If you stop or forget to take Contiflo-D for several days, talk with your healthcare provider before starting again.
• If you take too much Contiflo-D, call your healthcare provider or go to the nearest hospital emergency room right away.

What should I avoid while taking Contiflo-D?

• Avoid driving, operating machinery, or other dangerous activities when starting treatment with Contiflo-D until you know how Contiflo-D affects you. Contiflo-D can cause a sudden drop in your blood pressure, especially at the start of treatment. A sudden drop in blood pressure may cause you to faint, feel dizzy or lightheaded.
• You should not donate blood while taking Contiflo-D or for 6 months after you have stopped Contiflo-D. This is important to prevent pregnant women from receiving Contiflo-D through blood transfusions.

What are the possible side effects of Contiflo-D?

Contiflo-D may cause serious side effects, including:

• Decreased blood pressure. Contiflo-D may cause a sudden drop in your blood pressure upon standing from a sitting or lying position, especially at the start of treatment. Symptoms of low blood pressure may include:
• fainting
• dizziness
• feeling lightheaded
• Rare and serious allergic reactions, including:
• swelling of your face, tongue, or throat
• difficulty breathing
• serious skin reactions, such as skin peeling

Get medical help right away if you have these serious allergic reactions.

• Higher chance of a more serious form of prostate cancer.
• Eye problems during cataract surgery. During cataract surgery, a condition called Intraoperative Floppy Iris Syndrome (IFIS) can happen if you take or have taken Contiflo-D in the past. If you need to have cataract surgery, tell your surgeon if you take or have taken Contiflo-D.
• A painful erection that will not go away. Rarely, Contiflo-D can cause a painful erection (priapism), which cannot be relieved by having sex. If this happens, get medical help right away. If priapism is not treated, there could be lasting damage to your penis, including not being able to have an erection.

The most common side effects of Contiflo-D include:

• ejaculation problems*
• trouble getting or keeping an erection (impotence)*
• a decrease in sex drive (libido)*
• dizziness
• enlarged or painful breasts. If you notice breast lumps or nipple discharge, you should talk to your healthcare provider.
• runny nose

*Some of these events may continue after you stop taking Contiflo-D.

Depressed mood has been reported in patients receiving Contiflo-D, an ingredient of Contiflo-D.

Contiflo-D, an ingredient of Contiflo-D, has been shown to reduce sperm count, semen volume, and sperm movement. However, the effect of Contiflo-D on male fertility is not known.

Prostate-Specific Antigen (PSA) Test: Your healthcare provider may check you for other prostate problems, including prostate cancer before you start and while you take Contiflo-D. A blood test called PSA (prostate-specific antigen) is sometimes used to see if you might have prostate cancer. Contiflo-D will reduce the amount of PSA measured in your blood. Your healthcare provider is aware of this effect and can still use PSA to see if you might have prostate cancer. Increases in your PSA levels while on treatment with Contiflo-D (even if the PSA levels are in the normal range) should be evaluated by your healthcare provider.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects with Contiflo-D. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store Contiflo-D?

• Store Contiflo-D capsules at room temperature (59° to 86°F or 15° to 30°C).
• Contiflo-D capsules may become deformed and/or discolored if kept at high temperatures.
• Do not use or touch Contiflo-D if your capsules are deformed, discolored, or leaking.
• Safely throw away medicine that is no longer needed.

Keep Contiflo-D and all medicines out of the reach of children.

Medicines are sometimes prescribed for purposes other than those listed in a patient leaflet. Do not use Contiflo-D for a condition for which it was not prescribed. Do not give Contiflo-D to other people, even if they have the same symptoms that you have. It may harm them.

This patient information leaflet summarizes the most important information about Contiflo-D. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about Contiflo-D that is written for health professionals.

For more information, go to www. JALYN.com or call 1-888-825-5249.

What are the ingredients in Contiflo-D?

Active ingredients: Contiflo-D and tamsulosin hydrochloride

Inactive ingredients: black ink, butylated hydroxytoluene, carrageenan, FD&C yellow 6, ferric oxide (yellow), gelatin (from certified BSE-free bovine sources), glycerin, hypromellose, iron oxide red, methacrylic acid copolymer dispersion, microcrystalline cellulose, mono-di-glycerides of caprylic/capric acid, potassium chloride, talc, titanium dioxide, and triethyl citrate.

How does Contiflo-D work?

Contiflo-D contains 2 medications, Contiflo-D and tamsulosin. These 2 medications work in different ways to improve symptoms of BPH. Contiflo-D shrinks the enlarged prostate and tamsulosin relaxes muscles in the prostate and neck of the bladder. These 2 medications, when used together, can improve symptoms of BPH better than either medication when used alone.

Contiflo-D is a registered trademark of the GSK group of companies.

The other brands listed are trademarks of their respective owners and are not trademarks of the GSK group of companies. The makers of these brands are not affiliated with and do not endorse the GSK group of companies or its products.

Manufactured for:

GlaxoSmithKline

Research Triangle Park, NC 27709

©2015, the GSK group of companies. All rights reserved.

January 2015

JLN:9PIL

Contiflo-D pharmaceutical active ingredients containing related brand and generic drugs:

• Dutasteride
• Tamsulosin Hydrochloride

Contiflo-D available forms, composition, doses:

• Capsules; Oral; Dutasteride 0.5 mg / Tablet, Film-Coated; Oral; Tamsulosin Hydrochloride 0.4 mg

Contiflo-D destination | category:

• Human:
• Drugs for bladder and prostate disorders

Contiflo-D Anatomical Therapeutic Chemical codes:

• G04CA52 - Tamsulosin and Dutasteride

Contiflo-D pharmaceutical companies:

• Ranbaxy

References

1. Dailymed."FLOMAX (TAMSULOSIN HYDROCHLORIDE) CAPSULE [BRYANT RANCH PREPACK]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
2. Dailymed."AVODART (DUTASTERIDE) CAPSULE, LIQUID FILLED [LAKE ERIE MEDICAL & SURGCIAL SUPPLY DBA QUALITY CARE PRODUCTS LLC]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
3. Dailymed."DUTASTERIDE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).

Frequently asked Questions

Depending on the reaction of the Contiflo-D after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Contiflo-D not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

Review

Visitor reports

Visitor reviews

The information was verified by Dr. Rachana Salvi, MD Pharmacology